Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.
暂无分享,去创建一个
Rong Zhou | Hui Li | Gang Zheng | R. Zhou | J. Glickson | G. Zheng | Juan Chen | Hui Li | I. Corbin | Juan Chen | Ian R Corbin | Sissel Lund-Katz | Jerry D Glickson | S. Lund-Katz
[1] J. Pinotti,et al. Uptake of a cholesterol-rich emulsion by breast cancer. , 2002, Gynecologic oncology.
[2] R. Firestone,et al. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. , 1994, Bioconjugate chemistry.
[3] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[4] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[5] M. Piccinini,et al. Towards MRI contrast agents of improved efficacy. NMR relaxometric investigations of the binding interaction to HSA of a novel heptadentate macrocyclic triphosphonate Gd(III)-complex , 1997, JBIC Journal of Biological Inorganic Chemistry.
[6] S. Vitols,et al. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. , 1986, Cancer research.
[7] M C Phillips,et al. A 13C NMR characterization of lysine residues in apolipoprotein B and their role in binding to the low density lipoprotein receptor. , 1988, The Journal of biological chemistry.
[8] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[9] A. Hasso,et al. Efficacy evaluation of gadoteridol for MR angiography of intracranial vascular lesions , 1994, Journal of magnetic resonance imaging : JMRI.
[10] T. Vo‐Dinh,et al. Optical sensor for the detection of caspase-9 activity in a single cell. , 2004, Journal of the American Chemical Society.
[11] E. De Clercq,et al. Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. , 2001, Molecular pharmacology.
[12] T. Laudański,et al. Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug , 2004, Cancer Chemotherapy and Pharmacology.
[13] Enzo Terreno,et al. Contrast agents for magnetic resonance angiographic applications: 1H and 17O NMR relaxometric investigations on two gadolinium(III) DTPA-like chelates endowed with high binding affinity to human serum albumin , 1999, JBIC Journal of Biological Inorganic Chemistry.
[14] Jo Klaveness,et al. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. , 2002, International journal of pharmaceutics.
[15] J. Segrest,et al. Structure of apolipoprotein B-100 in low density lipoproteins. , 2001, Journal of lipid research.
[16] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[17] Shelton D Caruthers,et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. , 2003, Circulation.
[18] P. Urizzi,et al. Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): evaluation as a potential radiopharmaceutical for tumor localization. , 1996, Bioconjugate chemistry.
[19] A. Bjørnerud,et al. A targeted contrast agent for magnetic resonance imaging of thrombus: Implications of spatial resolution , 2001, Journal of magnetic resonance imaging : JMRI.
[20] Zahi A Fayad,et al. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. , 2004, Journal of the American Chemical Society.
[21] Stasia A. Anderson,et al. Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .
[22] R. Lees,et al. Adrenal imaging with technetium-99m-labelled low density lipoproteins. , 1986, Metabolism: clinical and experimental.
[23] T. Murakami,et al. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. , 1996, Radiology.
[24] Alan Pater,et al. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[25] H R Hoogenboom,et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.
[26] R. Lees,et al. 99mTechnetium-labeled low density lipoprotein: receptor recognition and intracellular sequestration of radiolabel. , 1991, Journal of lipid research.
[27] Sheng-Kwei Song,et al. Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.
[28] Hui Li,et al. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Bulte,et al. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. , 2004, Current pharmaceutical biotechnology.
[30] Indrajit Roy,et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. , 2003, Journal of the American Chemical Society.
[31] S A Wickline,et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. , 2000, Magnetic resonance in medicine.
[32] Leif Østergaard,et al. Cerebral Perfusion Imaging by Bolus Tracking , 2004, Topics in magnetic resonance imaging : TMRI.
[33] H. Blomgren,et al. Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells , 1985, Medical oncology and tumor pharmacotherapy.
[34] N. Tarasova,et al. Small molecule toxins targeting tumor receptors. , 2004, Current pharmaceutical design.
[35] S. Yanovich,et al. Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells. , 1984, Cancer research.
[36] S. H. Koenig,et al. The design of liposomal paramagnetic mr agents: effect of vesicle size upon the relaxivity of surface‐incorporated lipophilic chelates , 1992, Magnetic resonance in medicine.
[37] R. Zhou,et al. MR and fluorescent imaging of low-density lipoprotein receptors. , 2004, Academic radiology.
[38] W. Lautt,et al. Hepatic circulation and toxicology. , 1997, Drug metabolism reviews.
[39] D. Gómez-Coronado,et al. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. , 1998, Journal of lipid research.
[40] Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. , 2000, European journal of medicinal chemistry.
[41] J. Klaveness,et al. Preparation and in vitro evaluation of a novel amphiphilic GdPCTA-[12] derivative; a micellar MRI contrast agent. , 2003, Organic & biomolecular chemistry.
[42] R. Mahley,et al. Uptake of chemically modified low density lipoproteins in vivo is mediated by specific endothelial cells , 1985, The Journal of cell biology.
[43] S. Laurent,et al. Physicochemical Characterization of MS‐325, a New Gadolinium Complex, by Multinuclear Relaxometry , 1999 .
[44] E. Gianolio,et al. Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. , 2004, Current pharmaceutical biotechnology.
[45] C. Yuan,et al. Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease , 2004, The International Journal of Cardiovascular Imaging.
[46] S. Yamashita,et al. Marked hypocholesterolemia in a case with adrenal adenoma--enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. , 1995, The Journal of clinical endocrinology and metabolism.
[47] M. Krieger,et al. Reconstitution of the hydrophobic core of low-density lipoprotein. , 1986, Methods in enzymology.
[48] S. Caruthers,et al. Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. , 2004, Current pharmaceutical biotechnology.
[49] M. Brown,et al. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Urizzi,et al. Internalization of indium‐labeled LDL through a lipid chelating anchor in human pancreatic‐cancer cells as a potential radiopharmaceutical for tumor localization , 1997, International journal of cancer.
[51] D. Rhainds,et al. Low density lipoprotein uptake: holoparticle and cholesteryl ester selective uptake. , 1999, The international journal of biochemistry & cell biology.
[52] S. Vitols,et al. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. , 2002, Biochemical pharmacology.
[53] Y. Chen,et al. Human prostate cancer cells lack feedback regulation of low‐density lipoprotein receptor and its regulator, SREBP2 , 2001, International journal of cancer.
[54] H. Lodish,et al. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. , 1994, The Journal of biological chemistry.
[55] J. Goldstein,et al. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts , 1975, Cell.
[56] Hui Li,et al. High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. , 2005, Journal of biomedical optics.
[57] E. Koivunen,et al. Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. , 2004, Current pharmaceutical design.
[58] M. Phillips,et al. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. , 1998, Biochemistry.
[59] Britton Chance,et al. Tricarbocyanine cholesteryl laurates labeled LDL: new near infrared fluorescent probes (NIRFs) for monitoring tumors and gene therapy of familial hypercholesterolemia. , 2002, Bioorganic & medicinal chemistry letters.
[60] G. Soula,et al. Biodistribution study of 99mTc‐labeled LDL in B16‐melanoma‐bearing mice. Visualization of a preferential uptake by the tumor , 1993, International journal of cancer.
[61] E. Ruoslahti. Antiangiogenics meet nanotechnology. , 2002, Cancer cell.
[62] Britton Chance,et al. Carbocyanine labeled LDL for optical imaging of tumors1 , 2004 .
[63] M. Krieger. [34] Reconstitution of the hydrophobic core of low-density lipoprotein , 1986 .
[64] Thommey P. Thomas,et al. Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.
[65] S A Wickline,et al. Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.
[66] Samuel A. Wickline,et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .
[67] Alexander Petrovsky,et al. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. , 2002, Bioconjugate chemistry.
[68] M J Welch,et al. Metabolic imaging with gallium-68- and indium-111-labeled low-density lipoprotein. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[69] A. Leo,et al. Low density lipoprotein receptor and mRNA expression in human colorectal cancer. , 2001, Anticancer Research.
[70] Grace Hu,et al. Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.
[71] E. Simpson,et al. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. , 1981, American journal of obstetrics and gynecology.
[72] V. Runge,et al. Central Nervous System: Review of Clinical Use of Contrast Media , 2001, Topics in magnetic resonance imaging : TMRI.
[73] A. Niendorf,et al. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery , 1995, International journal of cancer.
[74] T. V. van Berkel,et al. Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. , 1996, Biochemical pharmacology.
[75] H. Schmidt,et al. Low-density lipoprotein receptor mRNA in human breast cancer cells: Influence by PKC modulators , 1997, Breast Cancer Research and Treatment.
[76] S. Vitols,et al. Low Density Lipoprotein as a Carrier of Cytostatics in Cancer Chemotherapy: Study of Stability of Drug-carrier Complexes in Blood , 2000, Journal of drug targeting.
[77] L. Chan,et al. Reversal of Hypercholesterolemia in Low Density Lipoprotein Receptor Knockout Mice by Adenovirus-mediated Gene Transfer of the Very Low Density Lipoprotein Receptor (*) , 1996, The Journal of Biological Chemistry.